These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2315704)

  • 41. [Do 'chondroprotective agents' agents exist in osteoarthritis? Required proof].
    Lequesne M; Cadet C
    Therapie; 1998; 53(1):7-16. PubMed ID: 9773094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simulated digest of a glucosamine-based equine nutraceutical modifies effect of IL-1 in a cartilage explant model of inflammation.
    Pearson W; Lindinger MI
    J Vet Pharmacol Ther; 2008 Jun; 31(3):268-71. PubMed ID: 18471150
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug treatment of osteoarthritis.
    Huskisson EC; Doyle DV; Lanham JG
    Clin Rheum Dis; 1985 Aug; 11(2):421-31. PubMed ID: 3899491
    [No Abstract]   [Full Text] [Related]  

  • 44. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.
    Mastbergen SC; Marijnissen AC; Vianen ME; Zoer B; van Roermund PM; Bijlsma JW; Lafeber FP
    Rheumatology (Oxford); 2006 Apr; 45(4):405-13. PubMed ID: 16287921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Animal experiments with pirprofen].
    Maier R
    Fortschr Med; 1985 Feb; 103(SPEC NO 7A):159-64. PubMed ID: 3872823
    [No Abstract]   [Full Text] [Related]  

  • 46. Non-steroidal anti-inflammatory drugs in medical practice. Past, present and future. Focus on piroxicam. Proceedings of a symposium. Hamburg, Germany, June 1985.
    Eur J Rheumatol Inflamm; 1987; 8(1):1-130. PubMed ID: 3622590
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of R and S enantiomers and a racemic mixture of carprofen on the production and release of proteoglycan and prostaglandin E2 from equine chondrocytes and cartilage explants.
    Armstrong S; Lees P
    Am J Vet Res; 1999 Jan; 60(1):98-104. PubMed ID: 9918155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study.
    Mastbergen SC; Jansen NW; Bijlsma JW; Lafeber FP
    Arthritis Res Ther; 2006; 8(1):R2. PubMed ID: 16356188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Histopathologic studies of the effect of acemetacin on the articular cartilage of monkeys].
    Jacobi H; Janda B; Schröder J; Pelster B; Horstmann H
    Med Welt; 1983 Nov; 34(45):1277-81. PubMed ID: 6606103
    [No Abstract]   [Full Text] [Related]  

  • 50. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation.
    Clutterbuck AL; Mobasheri A; Shakibaei M; Allaway D; Harris P
    Ann N Y Acad Sci; 2009 Aug; 1171():428-35. PubMed ID: 19723086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Degenerative joint disease.
    Buckwalter JA; Martin J
    Clin Symp; 1995; 47(2):1-32. PubMed ID: 7554763
    [No Abstract]   [Full Text] [Related]  

  • 53. Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents.
    Burkhardt D; Ghosh P
    Semin Arthritis Rheum; 1987 Nov; 17(2 Suppl 1):3-34. PubMed ID: 3333893
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical aspects of chrondroprotection.
    Huskisson EC
    Semin Arthritis Rheum; 1990 Feb; 19(4 Suppl 1):30-2. PubMed ID: 2315706
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of disease progression during nonsteroidal antiinflammatory drug treatment: imaging X-rays.
    Buckland-Wright C
    Osteoarthritis Cartilage; 1999 May; 7(3):343-4. PubMed ID: 10329325
    [No Abstract]   [Full Text] [Related]  

  • 56. [New data on on osteoarthritis. Towards better understanding of osteoarthritis].
    Letonturier P
    Presse Med; 2002 Sep; 31(29):1367. PubMed ID: 12398108
    [No Abstract]   [Full Text] [Related]  

  • 57. [Evaluation methods of osteoarthritis: apropos of the ECHODIAH study].
    Dougados M; Nguyen M; Berdah L; Lequesne M; Mazières B; Vignon E
    Rev Prat; 1996 Mar; 46(6 Spec No):S53-S56. PubMed ID: 8731733
    [No Abstract]   [Full Text] [Related]  

  • 58. New trends in the treatment of osteoarthritis.
    Pelletier JP; Martel-Pelletier J
    Semin Arthritis Rheum; 2005 Jun; 34(6 Suppl 2):13-4. PubMed ID: 16206950
    [No Abstract]   [Full Text] [Related]  

  • 59. Risk assessment and risk management. International Symposium on Chemical Mixtures: Risk Assessment and Management. The Jerry F. Stara Memorial Symposium. June 7-9, 1988, Cincinnati, Ohio. Proceedings.
    Toxicol Ind Health; 1989 Oct; 5(5):619-924. PubMed ID: 2683217
    [No Abstract]   [Full Text] [Related]  

  • 60. Drugs in inflammation. Proceedings of a symposium. June 28-29, 1990, Noordwijk, The Netherlands.
    Agents Actions Suppl; 1991; 32():13-247. PubMed ID: 2069080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.